| Host: |
Rabbit |
| Applications: |
WB/IHC |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-TNK2 (920-1038) is suitable for use in Western Blot and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.05% Proclin300, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:500-1:2000IHC-P 1:50-1:200 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
TNK2 |
| Gene ID: |
10188 |
| Uniprot ID: |
ACK1_HUMAN |
| Immunogen Region: |
920-1038 |
| Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 920-1038 of human TNK2 (NP_005772.3). |
| Immunogen Sequence: |
KANFSTNNSNPGARPPPPRA TARLPQRGCPGDGPEAGRPA DKIQMAMVHGVTTEECQAAL QCHGWSVQRAAQYLKVEQLF GLGLRPRGECHKVLEMFDWN LEQAGCHLLGSWGPAHHKR |
| Tissue Specificity | The Tyr-284 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages. It also shows a significant increase in expression in prostate cancers during the progressive stages. |
| Post Translational Modifications | Autophosphorylation regulates kinase activity. Phosphorylation on Tyr-518 is required for interaction with SRC and is observed during association with clathrin-coated pits. Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be induced by EGF and is lysosome-dependent. |
| Function | Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin. Binds to both poly- and mono-ubiquitin and regulates ligand-induced degradation of EGFR, thereby contributing to the accumulation of EGFR at the limiting membrane of early endosomes. Downstream effector of CDC42 which mediates CDC42-dependent cell migration via phosphorylation of BCAR1. May be involved both in adult synaptic function and plasticity and in brain development. Activates AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' and 'Tyr-363' thereby promoting its recruitment to androgen-responsive enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates MCF2, thereby enhancing its activity as a guanine nucleotide exchange factor (GEF) toward Rho family proteins. Contributes to the control of AXL receptor levels. Confers metastatic properties on cancer cells and promotes tumor growth by negatively regulating tumor suppressor such as WWOX and positively regulating pro-survival factors such as AKT1 and AR. Phosphorylates WASP. |
| Protein Name | Activated Cdc42 Kinase 1Ack-1Tyrosine Kinase Non-Receptor Protein 2 |
| Cellular Localisation | Cell MembraneNucleusEndosomeCell JunctionAdherens JunctionCytoplasmic Vesicle MembranePeripheral Membrane ProteinCytoplasmic SideCytoplasmic VesicleClathrin-Coated VesicleMembraneClathrin-Coated PitCytoplasmPerinuclear RegionCytosolThe Tyr-284 Phosphorylated Form Is Found Both In The Membrane And NucleusCo-Localizes With Egfr On EndosomesNuclear Translocation Is Cdc42-DependentDetected In Long Filamentous Cytosolic Structures Where It Co-Localizes With Ctps1 |
| Alternative Antibody Names | Anti-Activated Cdc42 Kinase 1 antibodyAnti-Ack-1 antibodyAnti-Tyrosine Kinase Non-Receptor Protein 2 antibodyAnti-TNK2 antibodyAnti-ACK1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
